Andrographolide in Sepsis: Mechanistic Basis, New Drug States, and Advanced Delivery Systems

Sepsis is a leading cause of preventable mortality, and effective adjunct therapies that recalibrate the host response remain scarce. Andrographolide, a diterpenoid lactone from Andrographis paniculata, shows anti-inflammatory, antioxidant, endothelial-protective, and immunomodulatory activity in experimental sepsis and related inflammatory models. This narrative review examines both the mechanistic basis and the translational constraints of andrographolide in sepsis, with emphasis on modulation of Toll-like receptor 4 signaling and downstream NF-κB/MAPK activation, restraint of NLRP3 inflammasome activity, mitigation of mitochondrial stress and danger-signal amplification, and preservation of endothelial barrier function while partially maintaining bacterial clearance. We also discuss the major pharmaceutical liabilities of andrographolide, including extremely low aqueous solubility and limited systemic exposure, and distinguish exposure-enabling solid-state strategies from delivery platforms with potential relevance to acute sepsis care. Because the direct evidence base remains largely preclinical and the available human data derive mainly from non-sepsis conditions, current findings support hypothesis generation and translational exploration rather than clinical positioning in sepsis. Future priorities include septic PK/PD definition, route-appropriate formulation development, entity-specific safety evaluation, and rigorous validation in clinically relevant models and trials. A flowchart detailing andrographolide’s formulation strategies and effects on sepsis-related targets.The flowchart details the transformation of andrographolide from A. paniculata into sepsis-relevant effects. Due to its low aqueous solubility, systemic exposure is limited. Key sepsis targets include reduced TLR4–NF-kB/MAPK, NLRP3 inflammasome/pyroptosis, ROS/HMGB1–RAGE amplification and endothelial dysfunction. Formulation strategies to enhance exposure involve solid-state optimization (cocrystals, co-amorphous systems, solid dispersions) and IV-compatible nanocarriers (lipid/polymer nanoparticles, solubilized injectables, targeted carriers). Goals are improved exposure, rapid delivery and timely treatment. Effects on sepsis include reduced pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta), enhanced endothelial barrier integrity (reduced leak and leukocyte adhesion) and decreased organ injury with better functional preservation and survival potential.